Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond

Hallin and colleagues demonstrate the preclinical activity of the KRAS(G12C)-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRAS(G12C) inhibition highlights both the promise and potential need for combinatorial strategies to optimally target KRAS(G12C)-driven cancers.